The tone for pharmaceutical and biotechnology M&A activity in 2017 has very much been set in January, with six deals worth more than $500 million and three exceeding $1 billion.
Those include the deal that could well turn out to be the biggest of 2017, the $30 billion purchase of Swiss biotech Actelion by the US healthcare giant Johnson & Johnson (NYSE:JNJ).
US biotech Celgene (Nasdaq: CELG) and French pharma major Ipsen (Euronext: IPN) also showed an openness to add assets through costly acquisitions, and other big names including Swiss giant Roche (ROG: SIX) and the USA's Eli Lilly (NYSE: LLY) were active too.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze